Aarti Pharmalabs Peer Comparison
NSE: AARTIPHARM | BSE: 543748
₹884.55
₹11.85
(1.36%)
As on 02-Nov-2026 11:34IST
Market cap
₹8,067 Cr
Revenue (TTM)
₹2,161 Cr
P/E Ratio
31.4
P/B Ratio
3.6
Div. Yield
0.4 %
Edit
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
8,067 | 32,701 | 32,099 | 18,206 | 16,776 |
Revenue (₹ Cr) |
2,161 | 1,593 | 9,779 | 1,684 | 3,522 |
Net Profit (₹ Cr) |
231.97 | 438.64 | -270.51 | -1.62 | 186.10 |
Net Margin (%) |
10.69 | 27.16 | -2.71 | -0.10 | 5.15 |
RoE (%) |
11.90 | 25.02 | -2.55 | 0.22 | 4.93 |
Price to Earnings |
31.43 | 74.47 | -- | -- | 90.15 |
Price-To-Book |
3.58 | 17.61 | 3.94 | 3.07 | 3.45 |
Income Statement (₹ Cr)
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,161.17 | 1,592.52 | 9,778.62 | 1,683.82 | 3,522.30 |
|
Total Income
|
2,169.77 | 1,615.23 | 9,993.26 | 1,695.30 | 3,613.20 |
|
Total Expenditure
|
1,674.46 | 969.32 | 8,578.44 | 1,287.94 | 2,771.50 |
|
EBITDA
|
486.71 | 623.20 | 1,200.18 | 395.88 | 750.80 |
|
Depreciation
|
117.33 | 41.96 | 887.82 | 288.26 | 449.10 |
|
EBIT
|
369.38 | 581.24 | 312.36 | 107.62 | 301.70 |
|
Interest
|
57.27 | 4.21 | 347.94 | 126.12 | 43.60 |
|
Other Income
|
8.60 | 22.71 | 214.64 | 11.47 | 90.90 |
|
Exceptional Items
|
-4.84 | 0.00 | -216.88 | -13.12 | -96.80 |
|
Profit before Tax
|
315.87 | 599.74 | -37.82 | -20.14 | 252.20 |
|
Provision for Tax
|
83.90 | 161.10 | 232.69 | -18.52 | 66.10 |
|
Profit after Tax
|
231.97 | 438.64 | -270.51 | -1.62 | 186.10 |
Liabilities (₹ Cr)
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,254.77 | 1,857.45 | 8,142.24 | 5,920.89 | 4,858.80 |
|
Minority Interest
|
0.00 | 0.51 | 0.55 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
311.57 | 47.15 | 5,213.99 | 1,001.58 | 616.80 |
|
Current Liabilities
|
1,259.54 | 253.37 | 5,158.51 | 1,663.61 | 1,182.90 |
|
Total Liabilities
|
3,481.71 | 1,983.96 | 17,723.32 | 8,222.05 | 7,054.70 |
Assets (₹ Cr)
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,067.79 | 1,132.12 | 10,687.30 | 6,364.60 | 3,950.40 |
|
Current Assets
|
1,656.55 | 1,012.00 | 7,253.65 | 1,697.49 | 1,948.10 |
|
Total Assets
|
3,481.71 | 1,983.96 | 17,723.32 | 8,222.05 | 7,054.70 |
|
Total Debt*
|
685.63 | 26.49 | 5,495.48 | 1,276.30 | 9.40 |
|
Net Current Assets
|
397.01 | 758.64 | 2,095.14 | 33.87 | 765.20 |
|
Contingent Liabilities
|
7.94 | 17.25 | 95.72 | 1,287.25 | 536.50 |
Cashflow (₹ Cr)
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
261.93 | 292.17 | 1,652.60 | 8.52 | 915.20 |
|
Cash Flow from Investing Activities
|
-430.72 | -265.94 | -826.03 | -494.98 | -860.40 |
|
Cash from Financing Activities
|
170.58 | 4.10 | -38.98 | 359.44 | -215.00 |
|
Net Cash Inflow / Outflow
|
1.80 | 30.33 | 787.59 | -127.02 | -160.20 |
Ratios
Profitability Ratios
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
ROCE (%)
|
10.77 | 32.42 | 1.24 | 0.44 | 9.48 |
|
ROE (%)
|
11.90 | 25.02 | -2.55 | 0.22 | 4.93 |
|
ROA (%)
|
6.54 | 22.40 | -1.56 | -0.02 | 2.82 |
|
EBIT Margin (%)
|
17.09 | 36.50 | 3.19 | 6.39 | 8.57 |
|
Net Margin (%)
|
10.69 | 27.16 | -2.71 | -0.10 | 5.15 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
13.38 | 45.18 | 9.43 | 10.66 | -5.99 |
|
EBIT Growth (%)
|
10.54 | 115.51 | -3.72 | -55.98 | -48.77 |
|
Net Profit Growth (%)
|
0.29 | 95.80 | -199.34 | -103.99 | -60.25 |
|
EPS Growth (%)
|
13.85 | 63.29 | -410.28 | -91.16 | -49.04 |
|
Book Value Growth (%)
|
6.71 | 26.03 | 0.33 | -0.75 | 2.11 |
Valuation Ratios
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
Price / Earnings
|
30.39 | 74.62 | -153.04 | 1,397.87 | 67.94 |
|
Price / Book Value
|
3.51 | 17.64 | 3.91 | 3.03 | 3.34 |
|
Dividend Yield (%)
|
0.40 | 0.06 | 0.00 | 0.00 | 0.31 |
|
EV/EBITDA
|
17.67 | 52.27 | 29.97 | 48.25 | 19.94 |
|
Market Cap (₹ Cr)
|
5,342.07 | 20,944.75 | 18,108.89 | 16,876.12 | 15,723.10 |
Solvency Ratios
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.07 | 0.02 | 0.55 | 0.10 | 0.00 |
|
Short term debt to equity ratio
|
0.22 | 0.00 | 0.09 | 0.10 | 0.00 |
|
Current Ratio
|
1.32 | 3.99 | 1.41 | 1.02 | 1.65 |
|
Quick Ratio
|
0.68 | 2.89 | 0.77 | 0.75 | 1.51 |
|
Interest Coverage
|
6.52 | 143.52 | 0.89 | 0.84 | 6.78 |
Operating Efficiency Ratios
| Aarti Pharmalabs | Acutaas Chemicals | Piramal Pharma | Onesource Specialty Pharma | Syngene Intl | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
31.69 | 22.50 | 23.05 | 61.34 | 10.94 |
|
Asset Turnover
|
0.61 | 0.81 | 0.56 | 0.20 | 0.53 |
|
Receivable days
|
116.23 | 88.98 | 78.20 | 140.79 | 50.33 |
|
Inventory Days
|
123.16 | 56.04 | 93.30 | 75.94 | 14.43 |
|
Payable days
|
133.87 | 99.95 | 226.14 | 225.76 | 17,487.50 |
|
Cash Conversion Cycle
|
105.52 | 45.07 | -54.64 | -9.03 | -17,422.74 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
